The Inscripta® Blog
December 21, 2021
Inscripta’s MAD7™ CRISPR Nucleases Helping Hudson River Biosciences Improve Plant Editing
In a recent webinar, Ben Mijts of Inscripta, and Gabino Sanchez of Hudson River Biotechnology, demonstrate how Inscripta’s MADzyme™ family of…
December 14, 2021
New Market Report Finds Near-Boundless Opportunity in Synthetic Biology
A new U.S. thematic market report from Barclays’ Equity Research team shines a spotlight on the tremendous potential in the Synthetic Biology…
December 7, 2021
Inside Inscripta: Reem Baraka, Sequencing
While Inscripta is a genome engineering company, we also make heavy use of DNA sequencing — so much that we have a high-capacity internal…
November 30, 2021
EBRC Malice Analysis Workshop: Assessing Biotechnology Research for Security Concerns
Biosecurity is one of the active areas of involvement for Inscripta. To ensure that our technologies are used safely and responsibly, we have…
November 23, 2021
Recap of SynBioBeta’s Chemicals & Materials Digital Conference
As we excitedly await the January 2022 in-person SynBioBeta Conference, the synbio community organizers are keeping the conversation alive…
November 16, 2021
Expanding the gene editing toolbox for Bacillus subtilis with the MAD7™ nuclease
A review article “The CRISPR toolbox for the gram-positive model bacterium Bacillus subtilis” published last month in Critical Reviews in…
November 9, 2021
Webinar: Hypothesis-Driven and Empirical Approaches to Engineering Biology
In a recent webinar organized the Global Institute for Food Security (GIFS), Patrick Westfall, Senior Director of Cell Biology at Inscripta,…
November 2, 2021
Inside Inscripta: Julie Chaves, Applications Development
Our Inscripta family wouldn’t be the same without talented scientists like Julie Chaves, who works on the applications development team at our…
October 26, 2021
Podcast: Why Genome Engineering Is Important for Amyris R&D
In a new podcast, Mendelspod host Theral Timpson interviewed Kirsten Benjamin, the vice president of R&D at Amyris.